N/A N=9,361 Systolic Blood Pressure Intervention Trial
Hypertension
Primary: Number of Participants With First Occurrence of a Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Stroke, Heart Failure (HF), or CVD Death — 243; 319…
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=174 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Aggressive Non-Hodgkin Lymphoma
Primary: Number of Patients With Grades II-IV Acute GVHD — 39; 22; 3 Participants
Phase 2 N=39 A Study of LY2523355 in Participants With Breast Cancer
Metastatic Breast Cancer
Primary: Change in Tumor Size (CTS) From Baseline to the End of Cycle 2 — -0.0; -0.1 log ratio of end of Cycle 2 to baseline — p=0.344
Phase 2 N=154 A Study of LY2541546 in Women With Low Bone Mineral Density
Osteoporosis
Primary: Change From Baseline to 52 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.065; 0.115; 0.142; 0.054 g/cm^2
Phase 3 N=18 Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease
Hepatitis C Virus (HCV)
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 100; 80.0 percentage of participants
Phase 1 N=18 A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Stomach Neoplasms
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 1; 2; 2 Participants
Phase 2 N=103 A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Ovarian Cancer · Non Small Cell Lung Cancer · Prostate Cancer
Primary: Percentage of Participants With a Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 0 percentage of participants
Phase 3 N=377 A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
Post-Ischemic Stroke
Primary: Proportion of Subjects Who Show at Least a 20% Improvement on the Two Minute Walk Test (2MinWT) at Week 12 — 17; 17; 23; 97 participants
Phase 2 N=90 Trial of Oral Valproic Acid for Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Mean Change in Visual Field Area From Baseline to 52 Weeks--III4e Isopter — -122.9; -112.0; -293.7; -237.1 Visual field area (degrees squared) — p=0.035
Phase 2 N=61 Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable · Leukemia · Lymphoma
Primary: Number of Participants With Adverse Events — 1; 31; 1; 22 Participants
Phase 3 N=508 Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)
HIV Infections
Primary: Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm — 95; 96 Percentage of participants
Phase 2 N=25 Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma
Leukemia · Lymphoma, Non-Hodgkin
Primary: Tumor Apoptosis — 7 Participants
N/A N=281 Way to Be Active III (Framing Incentives)
Sedentary Lifestyle
Primary: Proportion of Days Each Individual Walks 7000 Steps Per Day or More — 0.30; 0.35; 0.36; 0.45 Proportion of participant-days
N/A N=11 Primed vs. Unprimed rTMS in Chronic Stroke
Stroke
Primary: Change in Cortical Excitability: Paired-Pulse — -18; 18; 12 milivolt
N/A N=19 Connection to Care: Pilot Study of a Mobile Health Tool for Patients With Depression and Anxiety
Anxiety · Depression
Primary: App Acceptability as Measured by Number of Patient App Users Who Rate App Easy to Use and Time Spent Reasonable — 16 Participants